Gonadotrophin-releasing hormone (GnRH) regulates gonadotrophin biosynthesis and release in the anterior pituitary via specific receptors. Extrapituitary expression and action of GnRH have been demonstrated in several species. A possible role for GnRH in preimplantation embryonic development, endometrial preparation, and the implantation process has been previously suggested. Moreover, the presence of an immunoreactive GnRH in preimplantation embryos has been demonstrated in different species; however, there are no data for human embryos. We postulate that in humans GnRH may play a role in preimplantation embryonic development as well as in the implantation process. To examine this hypothesis, we assessed GnRH and GnRH-receptor mRNA and protein expression in human preimplantation embryos with three pronuclei. GnRH is expressed in peri-implantation human embryos at both the mRNA and protein level. GnRH-receptor mRNA is also present in the embryos studied. Immunohistochemical localization of GnRH showed intense staining in all the blastomeres at morula stage as well as in the trophectoderm and inner cell mass of the blastocysts. The results of the present study challenge the widely held view that GnRH has a predominantly central action, and suggests a pathway to describe a local role for the GnRH system in successful preimplantation embryonic development and implantation.
Introduction
The hypothalamic decapeptide gonadotrophin-releasing hormone (GnRH) is the key neuromodulator of mammalian reproduction. This hormone is released from the hypothalamus via the hypophyseal portal system and binds to specific receptors on the anterior pituitary, resulting in the stimulation of biosynthesis and release of follicle stimulating hormone (FSH) and luteinizing hormone (LH) (Conn et al., 1991) .
A variety of tissues in several mammalian species express an extrahypothalamic GnRH which is immunologically, biologically and chemically identical to the hypothalamic hormone (Hsueh et al., 1981; Chegini et al., 1996; Casañ et al., 1998; Raga et al., 1998a) . Moreover, the presence of low affinity/ high capacity binding sites for GnRH has been demonstrated in several extrapituitary organs, e.g. the placenta, endometrium, myometrium, breast, prostate, ovary and testis (Emons et al., 1993; Chegini et al., 1996; Raga et al., 1998a) .
Several GnRH agonists have been shown to have a direct action in these peripheral receptors both in vivo and in vitro, to mediate a stimulatory effect on spontaneous contraction of human myometrium and Fallopian tubes as well as inducing human chorionic gonadotrophin (HCG) release by the placenta (Petraglia et al., 1987; Iwashita et al., 1993; Siler-Khodr et al., 1997) .
GnRH agonists are now used routinely in conjunction with exogenous gonadotrophins in most ovulation induction protocols for assisted reproduction and in-vitro fertilization (IVF). The majority of investigators agree that the benefits of using these analogues are to reduce cancellation rates by preventing premature LH surge, and increasing the number of oocytes harvested and embryos transferred, leading to an overall higher pregnancy rate (Hughes et al., 1992) .
Several reports concerning inadvertent administration of GnRH agonist during early pregnancy have been described, and a possible positive role for GnRH in human early implantation has been suggested by this clinical experience (Balasch et al., 1993; Wilshire et al., 1993; Gartner et al., 1997) .
Preimplantation embryonic development and implantation is a complex series of steps that under normal circumstances begins even before the blastocyst reaches the uterine cavity and attaches to the endometrium. In order to complete this enigmatic process, there is an embryonic-maternal dialogue, in which the embryo and the endometrium induce changes in each other to promote embryonic development and endometrial receptivity (Tazuke et al., 1996) .
GnRH and its receptor have been detected in pre-and peri-implantation embryos, the Fallopian tubes, and uterine endometrium in different species (Asirvatham et al., 1994; Seshagiri et al., 1994; Murdoch et al., 1995) . Their potential role in embryo development, endometrial preparation, and the implantation process has also been previously suggested in both mouse and human (Yang et al., 1995; Raga et al., 1998a) . Strong evidence exists for GnRH analogues affecting embryonic development. In the presence of GnRH agonist, the proportion of mouse embryos reaching hatching blastocyst stages in vitro increased. Moreover, GnRH antagonist had a detrimental effect on preimplantation embryonic development which was totally reversed by the addition of GnRH agonist, suggesting a specific action on embryo development, rather than a non-specific or toxic effect (Raga et al., 1998b) .
No data are available from human embryos during the periattachment period, however, following embryo-endometrial adhesion, trophoblastic differentiation into cyto-and syncytiotrophoblast layers occurs, and both cell layers are known to produce GnRH as well as to express the GnRH receptor in the first trimester placenta (Lin et al., 1995) .
In the present study we have examined, for the first time, GnRH and GnRH-receptor mRNA in three pronuclear preimplantation human embryos at various developmental stages. We have demonstrated that immunoreactive GnRH is localized in the human embryo during cleavage and preimplantation embryonic development.
Materials and methods

Institutional approval and informed consent
For both ethical and practical reasons, this investigation was performed on pathologically fertilized embryos (three pronuclei). All patients who participated in this study by donating their polyspermic embryos gave informed consent. The protocol and the consent form had been approved by the Institutional Committee on the use of human subjects in research at Stanford University and conforms to guidelines established by the Ethics Committee of the American Society for Reproductive Medicine on human embryo research.
Polyspermic human preimplantation embryos obtained from the IVF programme at Stanford University Department of Gynecology and Obstetrics, were cultured under normal IVF conditions and processed either for reverse transcription-polymerase chain reaction (RT-PCR) or immunohistochemistry at different developmental stages.
RT-PCR analysis
Single embryos from 8-cell (n ϭ 5), compacted morula (n ϭ 5), and blastocyst stage (n ϭ 6) were examined by RT followed by two rounds of nested PCR using a modification of methods described previously Kruessel et al., 1997 Kruessel et al., , 1998 for β-actin (internal standard), GnRH and GnRH-receptor mRNA. Sequences of cDNA-clones for the mRNA that should be detected in single embryos; β-actin (Ponte et al., 1984) , GnRH (Adelman et al., 1986) and GnRH receptor (Chi et al., 1993) were obtained from the GenBank Database of the National Center for Biotechnology Information (NCBI, Internet address: www.2.ncbi.nlm.nih.gov/cgi-bin/ genbank). The corresponding primer-sequences were constructed with the help of the program OLIGO 5.0 Primer Analysis Software (National Bioscience, Plymouth, MN, USA) and synthesized by the Protein, Aminoacid and Nucleic Acid Facility (Stanford University Medical Center, Palo Alto, CA, USA). To ensure that the product detected resulted from amplification of cDNA rather than contaminating genomic DNA, primers were designed to cross intron/exon boundaries. As a negative control for specific primers, a defined volume of culture medium in which the embryos were cultured was subjected to the same RT-PCR reaction. The identity of all PCR-235 products were confirmed by sequence analysis. The primer cDNAsequences and the sizes of the amplified fragments are listed in Table I .
To detect the mRNA transcripts of single embryos with RT-PCR, the RT was performed with oligo d(T) 16 in order to transcribe all the cDNA fragments to be studied. For the specific primer mixture used in PCR, 3Ј and 5Ј primers of each specific outer pair for the first PCR and 3Ј and 5Ј primers of each specific inner pair for the second PCR were mixed to a final concentration of 5 µM.
RT mastermix for each embryo was prepared containing 5 µM MgCl 2 , 10ϫ PCR Buffer II, 1 mM of each dNTP (Perkin-Elmer, Foster City, CA, USA), 2.5 µM oligo d(T) 16 and filled in a 0.5 ml thin-walled PCR tube (Applied Scientific, San Francisco, CA, USA). RT mastermix in each PCR tube was covered with 50 µl of light white oil (Sigma, St Louis, MO, USA) and kept on ice until the embryo collection. One single embryo carrying~1 µl of culture medium was aspirated with a micropipette and transferred to the PCR tube containing 17.5 µl RT mastermix. Samples were immediately heated to 99°C for 1 min in a DNA thermal cycler 480 (PerkinElmer) to release the total RNA and denature the proteins. Samples were cooled down to 4°C and 20 IU of RNase inhibitor (PerkinElmer) and 100 IU Molony Murine Leukaemia Virus (M-MLV) reverse transcriptase (Gibco BRL, Grand Island, NY, USA) were added prior to starting RT. The RT reaction in a total volume of 20 µl was carried out in the DNA Thermal Cycler 480 using a programme with a 30 min RT cycle at 42°C, followed by 5 min at 99°C, then quenched at 4°C. Products were stored at -20°C until the subsequent PCR.
For the first PCR, 2 µl of RT product from an individual embryo was added to the first PCR mastermix to a total volume of 49.5 µl containing 2 mM MgCl 2 , 10ϫ PCR Buffer II, 0.24 mM of each dNTP, 0.24 µM 3Ј and 5Ј primers mixture of each specific outer pair and covered with 50 µl light white oil. PCR cycles were initiated by heading to 95°C for 5 min to denature all proteins and DNA, then at 95°C, 2.5 IU of AmpliTaq ® DNA Polymerase (Perkin-Elmer) was added to a total volume of 50µl. PCR was carried out for 30 cycles of 45 s at 94°C, 45 s at 56°C and 60 s at 72°C. The reaction was terminated at 72°C for 6 min and held at 4°C. First-round PCR products were stored at -20°C until the second round of PCR.
For the second round PCR, 5 µl of the initial PCR products were added to the second PCR mastermix to a total volume of 99.5 µl containing 1.9 mM MgCl 2 , 10ϫ PCR-Buffer II, 0.2 mM of each dNTP, 0.2 µM 3Ј and 5Ј primer mixture of each corresponding inner pair and covered with 50 µl light white oil. After completing the second round PCR using the same programme, samples were stored at -20°C until electrophoresis.
The PCR products were analysed by electrophoresis using a 2% agarose gel (Gibco), carried out in an H5 electrophoresis chamber, and stained with ethidium bromide (Sigma). Photocopies of the agarose gel were printed on the GelDoc 1000 system (Bio-Rad Laboratories, Hercules, CA, USA).
Immunohistochemical staining
Single preimplantation embryos at compacted morula (n ϭ 9), and blastocyst stages (n ϭ 7) were examined by an avidin-biotin alkaline phosphatase technique (De los Santos et al., 1996) in order to localize the GnRH at the protein level. Embryos were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 30 min at 4°C in microdrops under oil, and then treated with acid Tyrode's solution (pH 2.5) in order to induce permeabilization of the zona pellucida. To reduce the non-specific binding, 2% normal goat serum in PBS was applied to the embryos for 30 min at room temperature, then rinsed twice in PBS (pH 7.4) with 0.05% Tween-20 (PBS-T; Sigma) and incubated for 90 min at 37°C with the primary anti- body:rabbit antihuman-[Lys 8 ] GnRH at 1 µg/ml. After rinsing with PBS-T, the embryos were incubated for 90 min at room temperature with a secondary antibody:biotinylated anti-rabbit immunoglobulin (Ig)G (1:800 dilution; Sigma). Immunohistochemical controls were incubated with PBS containing 2% goat serum without primary antibody. To amplify the signal, embryos were washed with PBS-T and then the avidin-biotin alkaline phosphatase-staining method (Vector Laboratories Inc, Burlingame, CA, USA) was used. Endogenous alkaline phosphatase activity was inhibited by the addition of levamisole to the buffer used to prepare the substrate solution. Finally, embryos were incubated in alkaline phosphatase substrate solution until the red colour had developed; then the reaction was stopped in all the embryos simultaneously. A red precipitate indicated positive staining by the primary antibody. Embryos in microdrops under oil were visualized and photographed by a 35 mm camera (Olympus) attached to an inverted microscope (Olympus). Intensity of immunostaining was evaluated by the HSCORE (Lessey et al., 1995; De los Santos et al., 1996) . This method provides numeric value of the overall staining intensity and percentage of cells/embryos stained. The HSCORE is calculated using the equation: HSCORE ϭ SPi (i ϩ 1) where i ϭ intensity of staining with a value (obtained by two of the authors in a double-blind manner) of 1 (weak), 2 (moderate), or 3 (strong), and Pi is the percentage of stained embryos in every stage for each intensity.
Statistical analysis
Statistical significance was determined using a factorial analysis of variance followed by Fisher's least significant difference test using the Statistical Package for Social Science (SPSS Inc, Chicago, IL, USA). P Ͻ 0.05 was considered to be statistically significant.
Results
Expression of β-actin, GnRH and GnRH-receptor mRNA transcripts in individual embryos at different developmental stages
A total of 16 preimplantation human embryos were examined for β-actin, GnRH and GnRH-receptor mRNA expression. Electrophoresis of RT-PCR fragments of each individual embryo produced three different size bands corresponding to fragment sizes produced by specific primers used in the secondround PCR of DNA fragments for β-actin, GnRH and GnRHreceptor at embryo stages of 8-cell, compact morula, and expanded blastocyst as shown in Figure 1 .
All the embryos at each developmental stage expressed β- actin mRNA, thus confirming the integrity of the RNA and the RT-PCR process. Moreover, we were able to detect GnRH mRNA expression in three out of five (60%) 8-cell embryos studied, while all the morula stage and five out of six (83%) expanded blastocyst stage embryos were positive for GnRH mRNA expression. Furthermore, we were also able to detect GnRH-receptor mRNA expression in all the embryos at all embryonic developmental stages studied.
Immunohistochemical studies
Immunoreactive GnRH was identified in 16 embryos (nine at compacted morula stage, and seven at expanded blastocyst stage) during the preimplantation period using an avidin-biotin alkaline phosphatase technique. Immunohistochemical localization of GnRH showed intense staining in the cytoplasm and plasma membrane of the different blastomeres at compacted morula stage. Furthermore we were able to localize GnRH in the trophectoderm and inner cell mass of the expanded blastocysts. No cytoplasmic labelling was observed in control experiments (Figure 2) . The HSCORE for GnRH staining at each embryonic stage is shown in Table II . The comparison of immunostaining assessed at each developmental stage using analysis of variance with Scheffé's analysis revealed no statistical differences among different developmental stages.
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Discussion
This study demonstrates for the first time the mRNA expression of GnRH and GnRH-receptor in single pre-implantation human embryos. Furthermore, the immunoreactive presence of GnRH in human embryos during the peri-attachment period was demonstrated. Thus, our study confirms previous observations in peri-implantation rhesus monkey embryos, where an immunoreactive GnRH was demonstrated in in-vitro cultured embryos during the entire peri-attachment period (Seshagiri et al., 1994) . The immunohistochemical study localized the GnRH in the trophectoderm of the pre-hatched rhesus monkey blastocyst (Seshagiri et al., 1994) , consistent with our results. Furthermore, we were able to localize GnRH in the inner cell mass of the human blastocyst.
Preimplantation embryonic development and implantation itself is a complex series of steps that under normal circumstances begins following the loss of zona pellucida, even before the blastocyst reaches the uterine cavity and attaches at Pennsylvania State University on February 23, 2013 http://molehr.oxfordjournals.org/ Downloaded from to the endometrial epithelium. In order to complete this process, there is an embryonic-maternal dialogue, in which the embryo and the endometrium induce changes in each other to promote embryonic development and endometrial receptivity (Hearn et al., 1988; Paria et al., 1993; Simón et al., 1995) .
Cytokines, growth factors, and their receptors have been detected in pre-and peri-implantation embryos, the Fallopian tubes, and uterine endometrium (Hearn et al., 1988; Simon et al., 1995) . They have been implicated in embryo development, endometrial preparation, and the implantation process. For instance, pre-implantation embryos cultured in vitro lag in development compared to in vivo counterparts (Tazuke et al., 1996) . Pre-implantation embryonic development improves when the embryos are cocultured with other cells such as endometrial epithelium or Vero cells (De los Santos et al., 1996; Huang et al., 1997) . These observations suggest that while embryos can develop successfully in vitro, the maternal reproductive tract probably provides other factors that further enhance embryo development.
Mirroring the potential maternal contribution to embryonic development, embryos may induce changes in the maternal endometrium, beyond the influence of steroid milieu, to promote maternal receptivity. It has been suggested that growth factors and cytokines synthesized by pre-implantation embryos may enhance uterine receptivity directly by influencing the endometrial epithelial cells to undergo cellular changes (Simón et al., 1995; De los Santos et al., 1996) .
Recent studies demonstrate the existence of and possible role for GnRH and GnRH-receptor in human endometrium (Casañ et al., 1998; Raga et al., 1998a) , with special relevance in the luteal phase. The expression of GnRH mRNA in the human endometrium was found to be significantly increased in mid-luteal phase of fertile patients (Casañ et al., 1998; Raga et al., 1998a) . In addition, we have demonstrated that GnRH mRNA is expressed in freshly isolated endometrial epithelial and stromal cells at increased levels in the luteal phase, and immunoreactive GnRH was simultaneously localized to these epithelial and stromal cells (Raga et al., 1998a) . Furthermore, the presence of a GnRH and GnRH-receptor on the murine uterus with a possible paracrine role in the endometrial dynamic has also been suggested (Asirvatham et al., 1994; Murdoch et al., 1995) .
The establishment of mammalian pregnancy depends on the secretion of specific proteins by the conceptus (Prager et al., 1992) . Some of these proteins act directly or indirectly on the corpus luteum to maintain the secretion of progesterone, which in turn ensures an appropriate uterine milieu for the continued survival of the conceptus (Summers et al., 1993) . In primates, the product synthesized and secreted by the trophoblast of the implanting blastocyst is chorionic gonadotrophin (CG). Trophoblastic GnRH has been implicated as one of the primary regulators of the synthesis and secretion of CG both in periimplantation embryos (Seshagiri et al., 1994) and in the placenta (Petraglia et al., 1987; Prager et al., 1992) . This is consistent with the immunolocalization of GnRH in the trophectoderm of the blastocyst described in the present study, since during pregnancy the main site of HCG production is the syncytiotrophoblast.
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Unfortunately, little is known about the cellular and molecular mechanisms that lead to the initiation of CG synthesis and its secretion by the trophoblast of the primate blastocyst. Strong evidence from previous in-vitro studies in marmosets, baboons and humans (Summers et al., 1993) indicates that the uterine environment is not essential for the initiation of CG synthesis. In addition, there is evidence that while mural trophoblast from blastocysts can proliferate in vitro in the absence of the inner cell mass, efficient induction of CG secretion requires the presence of the inner cell mass or its derivatives (Summers et al., 1993) .
In the present study we have localized the presence of immunoreactive GnRH not only to the trophectoderm but also to the inner cell mass of the human blastocyst. This is concordant with our recent report in pre-implantation mice embryos, where immunoreactive GnRH was also localized to both the trophectoderm and inner cell mass of pre-hatched and hatched blastocyst (Raga et al., 1998b) .
Therefore, the presence of an immunoreactive GnRH in the inner cell mass of the blastocyst, along with the fact that GnRH is one of the primary regulators of the synthesis and secretion of CG in the trophoblast, opens up the possibility that this embryonic GnRH expression by the inner cell mass may be an early signal of HCG induction and secretion by the embryonic trophectoderm.
For both ethical and practical reasons we have conducted our study on triploid human embryos assessed by the number of pronuclei 16-18 h after IVF. These embryos were unsuitable for embryo transfer. The most crucial question regarding the biological significance of these findings is, whether or not they are influenced by the triploidy of these embryos. However, indications are that such embryos may be capable of relatively normal gene expression, as seen in polyploid embryos which are capable of an extensive, morphologically normal development far beyond the 8-cell stage (Jacobs et al., 1982) and reports of triploid birds (Werteleki et al., 1976) .
Previous studies have demonstrated a beneficial direct action for GnRH agonist both in vitro and in vivo on pre-implantation murine embryonic development and implantation (Summers et al., 1993) . Moreover, we have recently reported that infertile women undergoing IVF and embryo transfer, have significantly higher pregnancy and implantation rates if the administration of the GnRH agonist was maintained during the early stages of embryonic development and implantation (Raga et al., 1998c) .
The presence of GnRH in pre-implantation human embryos could provide a clue to the possible role of this decapeptide in pre-implantation embryonic development, and in the embryonic-maternal dialogue necessary for implantation. As our knowledge regarding extrahypothalamic GnRH increases with further studies, we may be able to translate this knowledge for facilitating pre-implantation embryonic development into clinical modalities to enhance or prevent embryonic implantation.
